Corium International (CORI) Given Coverage Optimism Rating of 0.19
Press coverage about Corium International (NASDAQ:CORI) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corium International earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6655016057516 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Corium International (CORI) opened at $11.20 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 6.80 and a current ratio of 7.04. Corium International has a one year low of $2.67 and a one year high of $11.37.
Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. The company had revenue of $8.11 million during the quarter, compared to the consensus estimate of $8.71 million. research analysts forecast that Corium International will post -1.74 EPS for the current fiscal year.
CORI has been the subject of several recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Corium International in a research report on Wednesday, July 19th. BidaskClub raised Corium International from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Zacks Investment Research cut Corium International from a “buy” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine cut Corium International from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $13.00 price objective on shares of Corium International in a report on Sunday, September 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Corium International presently has a consensus rating of “Buy” and an average price target of $13.00.
WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/06/corium-international-cori-given-coverage-optimism-rating-of-0-19.html.
In related news, CAO Timothy D. Sweemer sold 15,488 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $7.82, for a total value of $121,116.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Parminder Singh sold 32,000 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $7.61, for a total transaction of $243,520.00. The disclosure for this sale can be found here. Insiders have sold a total of 458,015 shares of company stock valued at $4,745,798 in the last quarter. Corporate insiders own 45.70% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.